Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
The FDA has signed off Sorrento Therapeutics Inc’s (NASDAQ:SRNE) Phase 3 trial of abivertinib in severe COVID-19 patients. The clinical trial…
Scilex Holding Company, A Majority-Owned Subsidiary Of Sorrento Therapeutics Enters Into Non-Binding Term Sheet For $5B Committed Equity Financing Facility To Be Effective In Connection With The Closing Of The Merger With Vickers Vantage
Scilex Holding Company ("Scilex"), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))), a commercial biopharmaceutical company focused on developing and
10 Biggest Price Target Changes For Friday
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.
Sorrento’s Chimeric mRNA COVID-19 Vaccine Candidate Shows Preclinical Action Against Omicron Variants
Sorrento Therapeutics Inc (NASDAQ:SRNE) announced the publication of a preprint entitled “Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron…
Sorrento’s Pain Company Reveals Final Results For SP-102 Data For Sciatica Pain Management
Sorrento Therapeutics Inc's (NASDAQ: SRNE) subsidiary Scilex Holding Company has announced final results from its SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program.
SP-102 (Semdexa) has received Fast Track status from the FDA.
Vickers Venture SPAC To Merge With Sorrento Therapeutics’ Pain-Focused Subsidiary
Vickers Venture Partners' special purpose acquisition company Vickers Vantage Corp I (NASDAQ: VCKA) will merge with Scilex Holding Company, focused on developing and commercializing non-opioid therapies for acute and chronic pain.
Scilex Holding Company, A Majority-Owned Subsidiary Of Sorrento Therapeutics, To Become Publicly Traded Through A Merger With Vickers Vantage Corp. I
Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before
